Ranbaxy forfeits 180 days exclusivity for generic Nexium

NEW DELHI: RanbaxyBSE 1.49 % Laboratories has lost the opportunity to exclusively market in the United States for six months the first generic version of Anglo Swedish drug innovator Astra Zeneca’s heartburn drug Nexium, the Delhi-based company said in a filing to the stock exchange on Tuesday.

The company, which is in the process of getting acquired by rival drugmaker Sun Pharmaceutical Industries, said the US Food and Drug Administration (FDA) has “determined that Ranbaxy has forfe ..